|
|
||||||||
proteins including human TRIM5
1 MRC Centre for Medical Molecular Virology, Division of Infection and Immunity, University College London, 46 Cleveland Street, London W1T 4JF, UK
2 Université de Lyon, (UCB-Lyon1), IFR128, Lyon, F-69007, France; INSERM, U758, Lyon, F-69007, France; Ecole Normale Supérieure de Lyon, Lyon, F-69007, France
Correspondence
Greg J. Towers
g.towers{at}ucl.ac.uk
| ABSTRACT |
|---|
|
|
|---|
molecules despite the fact that they strongly restrict a variety of divergent lentiviruses. We also show that the human PERV A/C recombinant clone 14/220 reverse transcribes with increased efficiency in human cells, leading to significantly higher infectivity. We conclude that xenotransplantation studies should consider the danger of highly infectious TRIM5
-insensitive human-tropic PERV recombinants. | INTRODUCTION |
|---|
|
|
|---|
TRIM5
has recently emerged as an important mediator of antiretroviral innate immunity in mammals. TRIM5
blocks retroviral infection in a species-specific way, for example human immunodeficiency virus type 1 (HIV-1) is restricted by TRIM5
from Old World monkeys, but not by human TRIM5
(Hatziioannou et al., 2004
; Stremlau et al., 2004
; Yap et al., 2004
). Human TRIM5
restricts infection by equine infectious anemia virus (EIAV) and the murine leukemia virus (MLV-N) (Hatziioannou et al., 2004
; Keckesova et al., 2004
; Yap et al., 2004
). TRIM5
encodes RING, B-box and coiled-coil domains, comprising a tripartite motif, as well as a C-terminal B30.2 domain, which determines antiviral specificity, and appears to interact directly with the incoming viral capsid (Stremlau et al., 2006a
). TRIM5
is thought to mediate an important barrier to zoonotic transmission of retroviruses by preventing replication early in the viral life cycle, usually before significant reverse transcription. The antiviral mechanism of TRIM5
remains incompletely characterized but appears to involve viral uncoating as well as recruitment to the proteasome (Anderson et al., 2006
; Stremlau et al., 2006a
; Wu et al., 2006
; reviewed by Towers, 2007)
. As PERVs have been suggested as a possible source of zoonotic infection after pig to human xenotransplantation we sought to examine the sensitivity of PERV isolates to restriction by mammalian TRIM5
molecules. Here, we show that two PERV isolates, prototypic PERV A PK (Bartosch et al., 2002
) and a high-titre PERV A/C recombinant PERV-A 14/220 (Bartosch et al., 2004
), are insensitive to restriction by divergent mammalian TRIM5
proteins. Furthermore, we show that the higher infectivity of the PERV A/C recombinant gag–pol is due to increased efficiency of reverse transcription.
| METHODS |
|---|
|
|
|---|
proteins from human, African green monkey (Keckesova et al., 2004
PERV A and A/C recombinant gag–pol expression vectors were generated by replacing the G ORF with PERV gag–pol derived from PERV A (GenBank accession no. AY099323
[GenBank]
) and/or PERV A/C 14/220 (GenBank accession no. AY570980
[GenBank]
) at the BamHI site in phCMV-G, by PCR (Bartosch et al., 2003
). Vesicular stomatitis virus glycoprotein (VSV-G) pseudotyped viral vectors derived from HIV-1 (Bainbridge et al., 2001
; Zufferey et al., 1997
), MLV (Bock et al., 2000
) and simian immunodeficiency virus mac (SIVmac) (Negre et al., 2000
) encoding green fluorescent protein (GFP) have been described elsewhere and were prepared by transfection of 293T cells as described previously (Besnier et al., 2002
). PERV GFP-encoding vectors were prepared similarly using a GFP-encoding genome derived from MLV (Naviaux et al., 1996
). PERV A/C gag–pol expression plasmids encoding PERV A protease, reverse transcriptase or integrase were constructed using the unique BclI site at the protease–reverse transcriptase junction or the unique HpaI site at the reverse transcriptase–integrase junction.
Western blot analysis.
A 1 ml sample of each viral supernatant, or supernatant from untransfected cells, was pelleted (123 000 g, 90 min) and resuspended in 30 µl Laemmli buffer. A volume of 10 µl was subjected to PAGE, blotted and detected using a rabbit anti-PERV polyclonal antibody (Bartosch et al., 2002
) (1 : 1000) and an anti-rabbit horseradish peroxidase linked antibody (1 : 3000; GE Healthcare).
Quantitative PCR (QPCR) to measure products of reverse transcription.
TaqMan QPCR to measure viral DNA synthesis was performed using primer/probe sequences specific to GFP as described previously (Passerini et al., 2006
). Cells (4x105) were infected in six-well plates in triplicate with equivalent doses of virus treated with DNase (70 U ml–1 for 2 h; Promega). Six hours after infection, total DNA was extracted from two samples using a QiaAmp DNA extraction kit (Qiagen). The third sample was subjected to FACS analysis 48 h after infection to enumerate infected cells. DNA (100 ng) was subjected to TaqMan QPCR as described previously (Towers et al., 1999
). Absolute numbers of GFP DNA per PCR were determined by reference to a standard curve. The number of GFP molecules per 100 ng total DNA were plotted. As a negative control for plasmid contamination of the viral inoculum, cells were infected with virus that had been boiled for 5 min. QPCR was then performed as described above.
| RESULTS |
|---|
|
|
|---|
proteins
we made gag–pol expression vectors for the prototypic PERV A PK and the PERV A/C 14/220 recombinant and used these plasmids to make VSV-G pseudotyped vectors packaging GFP-encoding MLV genomes as described previously (Besnier et al., 2002
proteins from human, African green monkey, rhesus macaque, squirrel monkey, rabbit or cattle or unmodified CRFK cells as a negative control, as described previously (Keckesova et al., 2004
s tested. The strongest restriction was by human TRIM5
, but this led to only around a threefold reduction in infectivity.
|
, titres of restriction-sensitive VSV-G pseudotyped GFP-encoding vectors were measured as above. In each case the viruses were selected for sensitivity to the TRIM5
in question. MLV-N infectivity was reduced by two to three orders of magnitude by expression of either human or African green monkey TRIM5
as described elsewhere (Hatziioannou et al., 2004
(Fig. 1c
, as described previously (Si et al., 2006
-insensitive control and was not affected by expression of any of the TRIM5
genes, as has been described previously (Hatziioannou et al., 2004
PERV A and PERV A/C VSV-G pseudotypes contain similar amounts of p30 capsid protein
Fig. 1
demonstrates that the titre of the VSV-G pseudotyped PERV A/C recombinant is significantly higher than that of the VSV-G pseudotyped PERV A. This is consistent with previous observations made comparing PERV A and PERV A/C viral replication in vitro (Bartosch et al., 2004
). In order to control for the dose of the two viruses we compared the amounts of PERV capsid in the virus stocks by Western blot analysis using a rabbit anti-PERV polyclonal antibody to detect PERV gag (Fig. 2
) (Bartosch et al., 2002
). The blot shows that the PERV A stocks (lanes 1 and 2) and PERV A/C stocks (lanes 3 and 4) have similar amounts of p30 capsid, demonstrating that each contained a similar concentration of virions. Supernatant from untransfected 293T cells and PERV A/C 14/220-infected cell lysate were blotted as controls (lanes 5 and 6, respectively).
|
|
| DISCUSSION |
|---|
|
|
|---|
. This is surprising given the broad antiviral activity of some TRIMs against distantly related lentiviruses. For example, bovine TRIM5
restricts all the lentiviruses tested against it, including HIV-1, HIV-2, SIVmac, feline immunodeficiency virus and EIAV (Si et al., 2006
restricts all but SIVmac (Schaller et al., 2007
s being MLV-B and the two PERVs described herein. Indeed, MLV-B and the two PERVs are not sensitive to any of the TRIM5
s tested. Whilst it is clear that these studies are limited by the relatively small number of viruses they employ, we believe that their diversity is broad enough to demonstrate that gammaretroviruses are significantly less sensitive to restriction by TRIM5
molecules. A recent study has suggested that human TRIM5
protected humans from a gammaretrovirus found endogenized in the chimpanzee genome referred to as ptERV (Kaiser et al., 2007
s restrict MLVs bearing ptERV capsids (Perez-Caballero et al., 2008
The reason for poor sensitivity of gammaretroviruses to TRIM5
may lie in the capsid structure. Intriguingly, the region of the capsid shown to influence primate lentiviral sensitivity to TRIM5
, referred to as the cyclophilin A-binding loop, is missing in the MLV capsid, although the rest of the N-terminal capsid structure is highly conserved (Mortuza et al., 2004
). As changes in the cyclophilin-binding loop affect primate lentiviral sensitivity to restriction by TRIM5
(Berthoux et al., 2005
; Keckesova et al., 2006
; Lin & Emerman, 2008
; Stremlau et al., 2006b
; Ylinen et al., 2005
), we speculate that this structure in gammaretroviruses has contributed to their general insensitivity to TRIM5
. It is striking that MLV-N is the only MLV shown to be restricted by TRIM5
(Hatziioannou et al., 2004
; Keckesova et al., 2004
; Perron et al., 2004
; Si et al., 2006
; Song et al., 2005
; Yap et al., 2004
; Ylinen et al., 2005
, 2006
). MLV-N is essentially a point mutant of MLV-B and we suspect that the E110 to R MLV-B capsid change was selected by evolutionary pressure from the murine antiviral Fv1 N, giving an advantage in Fv1 B-encoding mice but rendering it rather sensitive to restriction by TRIM5
.
The experiments performed here have made use of VSV-G pseudotyped retroviral vectors produced in human 293T cells and overexpression of TRIM5
proteins in CRFK cells. It is therefore possible that this experimental system might have influenced the results. However, this system has been very helpful in determining TRIM5
sensitivities in the past. Furthermore, it has been consistent with what we know of tropism of retroviruses in vivo, for example the lack of HIV-1 replication in monkeys, which can be bypassed, at least in vitro, by obviating TRIM5
and APOBEC3G restriction (Hatziioannou et al., 2006
). In our view, overexpression of TRIM5
in vitro is unlikely to lead to specificity artefacts, on the basis that TRIM5
is strongly induced by interferon and therefore protein levels are likely to be high during viral infection in vivo (Asaoka et al., 2005
; Sakuma et al., 2007
). Overexpression experiments are therefore a sensitive and relevant test of restriction sensitivity, although reduction of TRIM5
expression in relevant cell types and demonstration that PERV titres are not significantly affected would also augment the experiments described here.
We conclude that the two PERVs are not significantly restricted by any of the TRIM5
molecules tested (Fig. 1a
). The strongest restriction is threefold, by human TRIM5
, which is about the same magnitude that HIV-1 is restricted by human TRIM5
when overexpressed (Hatziioannou et al., 2003
; Newman et al., 2006
; Stremlau et al., 2004
; Yap et al., 2004
), indicating that it is unlikely to act as a barrier to PERV cross-species transmission. The two PERV sequences tested are likely to be representative of PERV classes A, B and C on the basis that the capsid sequences of these viruses are closely related (Fig. 4
). Not only are they highly conserved, but the residue corresponding to MLV CA 110 (indicated by an arrowhead in Fig 4
) known to influence MLV sensitivity to TRIM5
(Perron et al., 2004
; Towers et al., 2000
) is a conserved glutamate as it is in unrestricted MLV-B. This class of PERVs in general are therefore unlikely to be restricted by mammalian TRIM5
molecules. It is clear, however, that TRIM5
is not the only barrier to species-specific retroviral infection. Human APOBEC3G strongly restricts PERVs (Jonsson et al., 2007
) and human tetherin is likely to restrict PERVs, given that it restricts closely related MLVs (Neil et al., 2008
). There are also many other human TRIM proteins that may restrict PERVs (Nisole et al., 2005
). Our data therefore merely consider a single aspect of species barriers to zoonosis, which are likely to be complex and mediated by a large arsenal of species-specific antiviral proteins. Having said that, MLVs do appear to be particularly successful in transmitting between species, as illustrated by the diversity of gammaretroviral sequences in mammalian genomes, suggesting that they might be well adapted to avoiding restriction (Martin et al., 1999
, 2003
).
|
, underscores the need to consider the possibility of zoonotic transmission occurring in the context of pig to human xenotransplantation.
| ACKNOWLEDGEMENTS |
|---|
| REFERENCES |
|---|
|
|
|---|
Asaoka, K., Ikeda, K., Hishinuma, T., Horie-Inoue, K., Takeda, S. & Inoue, S. (2005). A retrovirus restriction factor TRIM5
is transcriptionally regulated by interferons. Biochem Biophys Res Commun 338, 1950–1956.[CrossRef][Medline]
Bainbridge, J. W., Stephens, C., Parsley, K., Demaison, C., Halfyard, A., Thrasher, A. J. & Ali, R. R. (2001). In vivo gene transfer to the mouse eye using an HIV-based lentiviral vector; efficient long-term transduction of corneal endothelium and retinal pigment epithelium. Gene Ther 8, 1665–1668.[CrossRef][Medline]
Bartosch, B., Weiss, R. A. & Takeuchi, Y. (2002). PCR-based cloning and immunocytological titration of infectious porcine endogenous retrovirus subgroup A and B. J Gen Virol 83, 2231–2240.
Bartosch, B., Dubuisson, J. & Cosset, F. L. (2003). Infectious hepatitis C virus pseudo-particles containing functional E1–E2 envelope protein complexes. J Exp Med 197, 633–642.
Bartosch, B., Stefanidis, D., Myers, R., Weiss, R., Patience, C. & Takeuchi, Y. (2004). Evidence and consequence of porcine endogenous retrovirus recombination. J Virol 78, 13880–13890.
Berthoux, L., Sebastian, S., Sokolskaja, E. & Luban, J. (2005). Cyclophilin A is required for TRIM5
-mediated resistance to HIV-1 in Old World monkey cells. Proc Natl Acad Sci U S A 102, 14849–14853.
Besnier, C., Takeuchi, Y. & Towers, G. (2002). Restriction of lentivirus in monkeys. Proc Natl Acad Sci U S A 99, 11920–11925.
Bock, M., Bishop, K., Towers, G. & Stoye, J. P. (2000). Use of a transient assay for studying the genetic determinants of Fv1 restriction. J Virol 74, 7422–7430.
Hanger, J. J., Bromham, L. D., McKee, J. J., O'Brien, T. M. & Robinson, W. F. (2000). The nucleotide sequence of koala (Phascolarctos cinereus) retrovirus: a novel type C endogenous virus related to Gibbon ape leukemia virus. J Virol 74, 4264–4272.
Hatziioannou, T., Cowan, S., Goff, S. P., Bieniasz, P. D. & Towers, G. J. (2003). Restriction of multiple divergent retroviruses by Lv1 and Ref1. EMBO J 22, 385–394.[CrossRef][Medline]
Hatziioannou, T., Perez-Caballero, D., Yang, A., Cowan, S. & Bieniasz, P. D. (2004). Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5
. Proc Natl Acad Sci U S A 101, 10774–10779.
Hatziioannou, T., Princiotta, M., Piatak, M., Jr, Yuan, F., Zhang, F., Lifson, J. D. & Bieniasz, P. D. (2006). Generation of simian-tropic HIV-1 by restriction factor evasion. Science 314, 95
Jonsson, S. R., LaRue, R. S., Stenglein, M. D., Fahrenkrug, S. C., Andresdottir, V. & Harris, R. S. (2007). The restriction of zoonotic PERV transmission by human APOBEC3G. PLoS One 2, e893[CrossRef][Medline]
Kaiser, S. M., Malik, H. S. & Emerman, M. (2007). Restriction of an extinct retrovirus by the human TRIM5
antiviral protein. Science 316, 1756–1758.
Keckesova, Z., Ylinen, L. M. & Towers, G. J. (2004). The human and African green monkey TRIM5
genes encode Ref1 and Lv1 retroviral restriction factor activities. Proc Natl Acad Sci U S A 101, 10780–10785.
Keckesova, Z., Ylinen, L. & Towers, G. J. (2006). Cyclophilin A renders HIV-1 sensitive to old world monkey but not human TRIM5
antiviral activity. J Virol 80, 4683–4690.
Le Tissier, P., Stoye, J. P., Takeuchi, Y., Patience, C. & Weiss, R. A. (1997). Two sets of human-tropic pig retrovirus. Nature 389, 681–682.[CrossRef][Medline]
Lieber, M. M., Sherr, C. J., Todaro, G. J., Benveniste, R. E., Callahan, R. & Coon, H. G. (1975). Isolation from the Asian mouse Mus caroli of an endogenous type C virus related to infectious primate type C viruses. Proc Natl Acad Sci U S A 72, 2315–2319.
Lin, T. Y. & Emerman, M. (2008). Determinants of cyclophilin A-dependent TRIM5
restriction against HIV-1. Virology 379, 335–341.[CrossRef][Medline]
Martin, J., Herniou, E., Cook, J., O'Neill, R. W. & Tristem, M. (1999). Interclass transmission and phyletic host tracking in murine leukemia virus-related retroviruses. J Virol 73, 2442–2449.
Martin, J., Kabat, P. & Tristem, M. (2003). Cospeciation and horizontal transmission rates in the murine leukaemia-related retroviruses. In Tangled Trees: Phylogeny, Cospeciation and Coevolution, pp. 174–194. Edited by R. D. M. Page. Chicago: University of Chicago Press.
Mortuza, G. B., Haire, L. F., Stevens, A., Smerdon, S. J., Stoye, J. P. & Taylor, I. A. (2004). High-resolution structure of a retroviral capsid hexameric amino-terminal domain. Nature 431, 481–485.[CrossRef][Medline]
Naviaux, R. K., Costanzi, E., Haas, M. & Verma, I. M. (1996). The pCL vector system: rapid production of helper-free, high-titre, recombinant retrovirus. J Virol 70, 5701–5705.
Negre, D., Mangeot, P. E., Duisit, G., Blanchard, S., Vidalain, P. O., Leissner, P., Winter, A. J., Rabourdin-Combe, C., Mehtali, M. & other authors (2000). Characterization of novel safe lentiviral vectors derived from simian immunodeficiency virus (SIVmac251) that efficiently transduce mature human dendritic cells. Gene Ther 7, 1613–1623.[CrossRef][Medline]
Neil, S. J., Zang, T. & Bieniasz, P. D. (2008). Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451, 425–430.[CrossRef][Medline]
Newman, R. M., Hall, L., Connole, M., Chen, G. L., Sato, S., Yuste, E., Diehl, W., Hunter, E., Kaur, A. & other authors (2006). Balancing selection and the evolution of functional polymorphism in Old World monkey TRIM5
. Proc Natl Acad Sci U S A 103, 19134–19139.
Niebert, M. & Tonjes, R. R. (2005). Evolutionary spread and recombination of porcine endogenous retroviruses in the suiformes. J Virol 79, 649–654.
Nisole, S., Stoye, J. P. & Saib, A. (2005). TRIM family proteins: retroviral restriction and antiviral defence. Nat Rev Microbiol 3, 799–808.[CrossRef][Medline]
Oldmixon, B. A., Wood, J. C., Ericsson, T. A., Wilson, C. A., White-Scharf, M. E., Andersson, G., Greenstein, J. L., Schuurman, H. J. & Patience, C. (2002). Porcine endogenous retrovirus transmission characteristics of an inbred herd of miniature swine. J Virol 76, 3045–3048.
Passerini, L. D., Keckesova, Z. & Towers, G. J. (2006). Retroviral restriction factors Fv1 and TRIM5
act independently and can compete for incoming virus before reverse transcription. J Virol 80, 2100–2105.
Patience, C., Takeuchi, Y. & Weiss, R. A. (1997). Infection of human cells by an endogenous retrovirus of pigs. Nat Med 3, 282–287.[CrossRef][Medline]
Patience, C., Switzer, W. M., Takeuchi, Y., Griffiths, D. J., Goward, M. E., Heneine, W., Stoye, J. P. & Weiss, R. A. (2001). Multiple groups of novel retroviral genomes in pigs and related species. J Virol 75, 2771–2775.
Perez-Caballero, D., Soll, S. J. & Bieniasz, P. D. (2008). Evidence for restriction of ancient primate gammaretroviruses by APOBEC3 but not TRIM5
proteins. PLoS Pathog 4, e1000181.[CrossRef][Medline]
Perron, M. J., Stremlau, M., Song, B., Ulm, W., Mulligan, R. C. & Sodroski, J. (2004). TRIM5
mediates the postentry block to N-tropic murine leukemia viruses in human cells. Proc Natl Acad Sci U S A 101, 11827–11832.
Rambaut, A. (1996). Se-Al: Sequence Alignment Editor. Distributed by the author. Department of Zoology, University of Oxford, South Parks Road, Oxford OX1 4JD, UK. Available online at http://tree.bio.ed.ac.uk/software/seal/
Sakuma, R., Mael, A. A. & Ikeda, Y. (2007). Alpha interferon enhances TRIM5
-mediated antiviral activities in human and rhesus monkey cells. J Virol 81, 10201–10206.
Schaller, T., Hue, S. & Towers, G. J. (2007). An active TRIM5 in rabbits indicates an antiviral common ancestor for mammalian TRIM5 proteins. J Virol 81, 11713–11721.
Si, Z., Vandegraaff, N., O'Huigin, C., Song, B., Yuan, W., Xu, C., Perron, M., Li, X., Marasco, W. A. & other authors (2006). Evolution of a cytoplasmic tripartite motif (TRIM) protein in cows that restricts retroviral infection. Proc Natl Acad Sci U S A 103, 7454–7459.
Song, B., Javanbakht, H., Perron, M., Park, D. H., Stremlau, M. & Sodroski, J. (2005). Retrovirus restriction by TRIM5
variants from Old World and New World primates. J Virol 79, 3930–3937.
Stoye, J. P. & Coffin, J. M. (1995). The dangers of xenotransplantation. Nat Med 1, 1100[Medline]
Stoye, J. P., Le Tissier, P., Takeuchi, Y., Patience, C. & Weiss, R. A. (1998). Endogenous retroviruses: a potential problem for xenotransplantation? Ann N Y Acad Sci 862, 67–74.[CrossRef][Medline]
Stremlau, M., Owens, C. M., Perron, M. J., Kiessling, M., Autissier, P. & Sodroski, J. (2004). The cytoplasmic body component TRIM5
restricts HIV-1 infection in Old World monkeys. Nature 427, 848–853.[CrossRef][Medline]
Stremlau, M., Perron, M., Lee, M., Li, Y., Song, B., Javanbakht, H., Diaz-Griffero, F., Anderson, D. J., Sundquist, W. I. & Sodroski, J. (2006a). Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5
restriction factor. Proc Natl Acad Sci U S A 103, 5514–5519.
Stremlau, M., Song, B., Javanbakht, H., Perron, M. & Sodroski, J. (2006b). Cyclophilin A: an auxiliary but not necessary cofactor for TRIM5
restriction of HIV-1. Virology 351, 112–120.[CrossRef][Medline]
Takeuchi, Y., Patience, C., Magre, S., Weiss, R. A., Banerjee, P. T., Le Tissier, P. & Stoye, J. P. (1998). Host range and interference studies of three classes of pig endogenous retrovirus. J Virol 72, 9986–9991.
Tarlinton, R. E., Meers, J. & Young, P. R. (2006). Retroviral invasion of the koala genome. Nature 442, 79–81.[CrossRef][Medline]
Towers, G. J. (2007). The control of viral infection by tripartite motif proteins and cyclophilin A. Retrovirology 4, 40[CrossRef][Medline]
Towers, G. J., Stockholm, D., Labrousse-Najburg, V., Carlier, F., Danos, O. & Pages, J. C. (1999). One step screening of retroviral producer clones by real time quantitative PCR. J Gene Med 1, 352–359.[CrossRef][Medline]
Towers, G., Bock, M., Martin, S., Takeuchi, Y., Stoye, J. P. & Danos, O. (2000). A conserved mechanism of retrovirus restriction in mammals. Proc Natl Acad Sci U S A 97, 12295–12299.
Wilson, C. A., Wong, S., VanBrocklin, M. & Federspiel, M. J. (2000). Extended analysis of the in vitro tropism of porcine endogenous retrovirus. J Virol 74, 49–56.
Wu, X., Anderson, J. L., Campbell, E. M., Joseph, A. M. & Hope, T. J. (2006). Proteasome inhibitors uncouple rhesus TRIM5
restriction of HIV-1 reverse transcription and infection. Proc Natl Acad Sci U S A 103, 7465–7470.
Yap, M. W., Nisole, S., Lynch, C. & Stoye, J. P. (2004). Trim5
protein restricts both HIV-1 and murine leukemia virus. Proc Natl Acad Sci U S A 101, 10786–10791.
Ylinen, L. M. J., Keckesova, Z., Wilson, S. J., Ranasinghe, S. & Towers, G. J. (2005). Differential restriction of human immunodeficiency virus HIV-2 and simian immunodeficiency virus SIVmac by TRIM5
alleles. J Virol 79, 11580–11587.
Ylinen, L. M., Keckesova, Z., Webb, B. L., Gifford, R. J., Smith, T. P. & Towers, G. J. (2006). Isolation of an active Lv1 gene from cattle indicates that tripartite motif protein-mediated innate immunity to retroviral infection is widespread among mammals. J Virol 80, 7332–7338.
Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L. & Trono, D. (1997). Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 15, 871–875.[CrossRef][Medline]
Received 16 September 2008;
accepted 26 November 2008.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |